{"id":"NCT03591068","sponsor":"Optinose US Inc.","briefTitle":"Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video","officialTitle":"A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-07","primaryCompletion":"2019-02-22","completion":"2019-02-22","firstPosted":"2018-07-18","resultsPosted":"2020-08-03","lastUpdate":"2020-08-03"},"enrollment":11,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nasal Polyposis"],"interventions":[{"type":"DRUG","name":"Fluticasone Propionate","otherNames":[]}],"arms":[{"label":"OPN-375 186 mcg BID","type":"EXPERIMENTAL"}],"summary":"This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.","primaryOutcome":{"measure":"Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video","timeFrame":"Week 24","effectByArm":[{"arm":"OPN-375 186 mcg BID","deltaMin":-0.7,"sd":0.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Dyspnea","Asthma","Back Pain","Dizziness","Fungal Skin Infection"]}}